Tag: Biopharmaceutical Development

Pharmaceutical companies are radically redesigning portfolio strategies to survive a "triple threat" environment of scientific complexity, regulatory upheaval like the IRA, and capital scarcity. This analysis explores the shift from efficiency-driven models to resilience-first frameworks, detailing how leaders are embedding optionality into pipelines, embracing modality agnosticism, and using dynamic resource allocation to thrive amidst volatility.

Thermo Fisher Scientific has gone on to announce quite a major expansion of its Bioprocess Design Centers in Asia, hence deepening its investment within...

IQVIA, known across the life sciences industry for its clinical research operations, commercial analytics, and health-data expertise, has entered a strategic collaboration with Amazon...

Regeneron Pharmaceuticals is going ahead and investing more funds into gene editing, as it has announced a collaboration with Tessera Therapeutics in December 2025,...

Azerbaijan and Jordan are looking out for new opportunities in order to establish a joint pharmaceutical venture, thereby signalling a very robust step towards...

The FDA has gone on to propose certain new policies in order to accelerate biosimilar drug development and at the same time also lower...

Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities...